<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    AC Immune SA

    AC Immune SA

    We are a clinical stage biopharmaceutical company leveraging our two proprietary t...

    We are a clinical stage biopharmaceutical compa...

    Filing Type:    PU
    DirectCare, Inc.

    DirectCare, Inc.

    Kumba Health is an online platform connecting doctors with patients. Kumba Health ...

    Kumba Health is an online platform connecting d...

    Fundraising Status:    SD
    Filing Type:    CF
    DexCom, Inc.

    DexCom, Inc.

    Founded in 1999, Dexcom, Inc. is the leader in transforming diabetes care and mana...

    Founded in 1999, Dexcom, Inc. is the leader in ...

    Filing Type:    PU
    iCAD inc.

    iCAD inc.

    iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...

    iCAD, Inc. an industry-leading provider of adva...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    BioHealthonomics Inc.

    BioHealthonomics Inc.

    BioHealthonomics Inc. is a research and development biotechnology & healthcare com...

    BioHealthonomics Inc. is a research and develop...

    Amount Raised:    $35,800
    Fundraising Status:    EC
    Filing Type:    CF
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Cytosorbents Corporation

    Cytosorbents Corporation

    CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...

    CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...

    Filing Type:    PU
    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...

    SELLAS Life Sciences Group, Inc. is a late-stag...

    Filing Type:    PU
    Benitec Biopharma Limited

    Benitec Biopharma Limited

    Benitec is a biotechnology company developing a proprietary therapeutic technology...

    Benitec is a biotechnology company developing a...

    Filing Type:    PU
    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...

    Atara Biotherapeutics is a leading off-the-shel...

    Filing Type:    PU
    Erytech Pharma S.A.

    Erytech Pharma S.A.

    Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...

    Founded in Lyon, France in 2004, ERYTECH is a c...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.